Exclusive-US FDA brass pushed internally for speedier Lilly weight-loss pill verdict

Leaders at the U.S. Food and Drug Administration have pressed internally for reviewers to speed up their evaluation of Eli ...

FDA Weighs Rapid Review For Eli Lilly Obesity Pill As Novo Nordisk Nears Launch

FDA may expedite approval timeline for Eli Lilly's weight-loss treatment, potentially moving decision date to late March from ...

A better Ozempic? Eli Lilly’s new obesity drug cut weight by 23%, study finds

In an added benefit, more than one in eight people taking the highest dose of Retratrutide were completely free of arthritic ...
BioPharma Dive

Lilly’s three-pronged drug puts obesity field ‘on notice’

Lilly’s closely watched retatrutide spurred as much as 29% weight loss in a Phase 3 study, a finding that is “raising the bar ...
Fierce Pharma

Lilly shifts ambition for broader oral SERD label to largest oncology trial in company history

Eli Lilly will not seek a broad FDA approval for a combination of the company’s oral SERD med Inluriyo and CDK4/6 inhibitor ...

Eli Lilly’s Latest Obesity Drug Delivers Strong Results. It Might Work Too Well.

Eli Lilly released trial results for its weight-loss drug candidate, retatrutide. The data showed high rates of weight loss, ...